SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C.  20549
                   __________________________________________
                                   FORM 10-KSB
(Mark  one)
[_]  Annual report  under  section 13 or 15(d) of the Securities Exchange Act of
     1934
                   For the fiscal year ended ________________

                                       OR

[X]  Transition  report under section 13 or 15(d) of the Securities Exchange Act
     of 1934

      For the transition Period from January 1, 2000 to September 30, 2000

                    Commission file number:       0-30096
                                           ------------------

                                    Home.Web, Inc.
                  --------------------------------------------
                 (Name of small business issuer in its charter)

                Nevada                                    77-0454933
         --------------------                         ------------------
    (State or other jurisdiction of                   (I.R.S. Employer
     incorporation or organization)                  Identification No.)

                  435 Martin Street
                  Blaine, Washington                         98230
        -------------------------------------          -----------------
       (Address of principal executive offices)            (Zip Code)

                    Issuer's telephone number: (360) 332-1350

Securities registered under Section 12(b) of the Act:
                 (Title  of  Class)                          Name of exchange on
                                                             which  registered

              None                                           None
----------------------------------           -----------------------------------

Securities registered under Section 12(g) of the Act:       Common Stock,
                                                          $0.001 par value
                                                     ---------------------------
                                                          (Title of class)

Check  whether  the Issuer (1) filed all reports required to be filed by Section
13  or  15(d)  of  the Securities Exchange Act during the past 12 months (or for
such  shorter period that the registrant was required to file such reports), and
(2)  has  been  subject  to  such  filing  requirements  for  the  past 90 days.
     Yes   X       No
          ---         ---

Check  if there is no disclosure of delinquent filers in response to Item 405 of
Regulation  S-B  is  not  contained  in  this  form,  and  no disclosure will be
contained,  to  the  best  of  registrant's  knowledge,  in  definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or  any  amendment  to  this  Form  10-KSB. [X]

Registrant's  revenues  for  its  most  recent  fiscal  year:  $Nil
                                                               ----

The  aggregate  market  value  of the voting stock held by non-affiliates of the
registrant  on  November 30, 2000, computed by reference to the closing price of
that  date,  was  $119,643,450, assuming solely for purposes of this calculation
that  all directors and executive officers of the issuer are "affiliates."  This
determination  of affiliate status is not necessarily a conclusive determination
for  other  purposes.

On  November  30,  2000,  the  registrant had 32,876,400 shares of Common Stock,
$0.001  par  value  per  share,  issued  and  outstanding.


            TRANSITIONAL SMALL BUSINESS DISCLOSURE FORMAT:  Yes [_]   No [X]


<PAGE>
<TABLE>
<CAPTION>
                                 HOME.WEB, INC.

                                    INDEX TO
                          ANNUAL REPORT ON FORM 10-KSB
          FOR THE NINE MONTH TRANSITION PERIOD ENDED SEPTEMBER 30, 2000

<S>         <C>                                                                                      <C>
PART  I                                                                                              PAGE
Item  1     Description  of  Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3
Item  2     Description  of  Property . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  8
Item  3     Legal  Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Item  4     Submission  of  Matters  to  a  Vote  of  Security  Holders . . . . . . . . . . . . . . . .9

PART  II
Item  5     Market  for  Common  Equity  and  Related  Stockholder Matters . . . . . . . . . . . . . . 9
Item  6     Management's Discussion and Analysis of Financial Condition and Results of Operations . . 10
Item  7     Financial  Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Item  8     Changes In and Disagreements With Accountants on Accounting and Financial Disclosure . . .14

PART  III
Item  9     Directors, Executive Officers, Promoters and Control Persons; Compliance With
            Section  16(a)  of  the  Exchange  Act . . . . . . . . . . . . . . . . . . . . . . . . . .15
Item  10    Executive  Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Item  11    Security  Ownership  of  Certain  Beneficial  Owners and Management . . . . . . . . . . . 17
Item  12    Certain  Relationships  and  Related  Transactions . . . . . . . . . . . . . . . . . . .  18
Item  13    Exhibits  and  Reports  on  Form  8-K . . . . . . . . . . . . . . . . . . . . . . . . . . 18

SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20

FINANCIAL STATEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .F-1
</TABLE>



                                        2
<PAGE>
                                     PART I

ITEM  1.  DESCRIPTION  OF  BUSINESS
-----------------------------------

Certain  statements  contained  in  this  Report, including, without limitation,
statements containing the words, "believes," "anticipates," "expects," and other
words  of  similar  import,  constitute  "forward-looking statements" within the
meaning  of  Section  27A of the Securities Act of 1933, as amended, and Section
21E  of  the  Securities Exchange Act of 1934, as amended.  Such forward-looking
statements  involve  known  and  unknown  risks, uncertainties and other factors
which  may  cause  the  actual results, performance or achievements of Home.Web,
Inc.  to  be  materially  different  from  any  future  results, performance, or
achievements  expressed  or  implied  by  such forward-looking statements. Given
these  uncertainties,  readers are cautioned not to place undue reliance on such
forward-looking  statements.  Home.Web,  Inc. disclaims any obligation to update
any  such  factors  or  to  announce publicly the results of any revision of the
forward-looking  statements  contained  or  incorporated  by reference herein to
reflect  future  events  or  developments.

THE  COMPANY

Home.Web,  Inc.  (the "Company") is a Nevada corporation formed on September 15,
1995  with  authorized  capital  of 50,000,000 shares of Common Stock, par value
$0.001  per  share, and 32,876,400 shares of issued and outstanding Common Stock
as  of  November  30,  2000.  The  Company  has been a development stage company
specializing  in  the wholesaling of specialty and gourmet cheeses.  The Company
suspended  operations  in  the  year  2000.

On October 16, 2000, the Company conducted a voluntary share exchange whereby it
offered  up to 28,800,000 shares of its Common Stock to the shareholders of Duro
Enzyme  Products  Inc.  ("Duro  Enzyme")  in  exchange for all of the issued and
outstanding  shares  of  Duro  Enzyme.  The  effect of the share exchange was to
transfer control of the Company to the shareholders of Duro Enzyme. The majority
of  shares  of  the  Company are now held by former shareholders of Duro Enzyme.
The  Company  effectively  took  control  of  all  of the assets of Duro Enzyme,
including  its  subsidiaries,  by  becoming its sole shareholder.  Following the
share exchange, the Company has offices in both Canada and the United States and
has  changed  the  focus  of  its business from gourmet and specialty cheeses to
DuroZyme technology.  Its Canadian office is located adjacent to the site of its
Technology  Development  Center  in  Langley,  British  Columbia.

The  Company  changed  its  fiscal  year end from December 31 to September 30 by
unanimous  consent  of  the  Board  of  Directors  on  December  15,  2000.

The  Company  now  has the license to utilize and exploit the DuroZyme plant and
3SF  Technology  anywhere  in the world.  Through application of the technology,
the Company can manufacture unique, stable and natural enzymes and specialty end
products.  This technology solves a major environmental problem and provides the
world  with  unique,  stable  and  natural  enzyme  products.

The  Company  is  structured as an integrated business with several subsidiaries
dedicated  to delivering distinct aspects of its overall mandate.  The following
shows  how  the  Company  is  organized  to  serve its clients and shareholders:

                            DURO  ENZYMES  PRODUCTS  INC.
                            ------------------------------
                            |                            |
                            |                            |
     DURO  ENZYME  SOLUTIONS  INC.          DURO  ENZYME  SOLUTIONS  INC.
     -----------------------------          -----------------------------
          (U.S.  Subsidiary)                    (Canadian  Subsidiary)
                  |                                            |
                  |                                            |
            DUROZYME  PLANT                    DURO  ENZYME  MANAGEMENT
            ---------------                   -------------------------

Both  of  the  Duro  Enzyme  Solutions Inc. subsidiaries are wholly owned by the
Company.  The  U.S.  subsidiary  owns  100%  of the prototype DuroZyme plant and
holds  the worldwide license to utilize and distribute products based on the 3SF
Technology.  The  U.S. subsidiary is responsible for managing and operating Duro
Enzyme's Technology Development Center, including researching and developing new
products  and  the  protection  of  intellectual  property.


                                        3
<PAGE>
The  Canadian  subsidiary  owns  100%  of  Duro  Enzyme  Management,  which  is
responsible for marketing, distributing, researching and siting DuroZyme plants,
products  and  services.   The  Canadian subsidiary will also provide management
and  operations  support  services,  arrange  for  and  secure financing for the
production  of plants, arrange for and secure long-term put-or-pay contracts for
selected  specific  input  organic  materials  and  arrange for and secure sales
contracts  for  DuroZyme  and  specialty  end  products.

The initial DuroZyme plants will be wholly owned and operated by the Company and
run  as  autonomous business entities.  Plants will be strategically sited in or
near  major urban centers.  Each operating division and DuroZyme plant under the
Company's  corporate  structure  will  have  access  to  a large pool of skilled
personnel,  including  experienced  managers, business consulting professionals,
research  and  process  technicians,  plant  operators  and  general  laborers.

Products,  Process  and  Market  Opportunity
--------------------------------------------

DuroZyme  plants  are  delivered  as  a  turnkey  package.  The  plants  take in
specific, selected organic materials and charge a processing fee to convert them
to  enzymes  with  unique,  stable  properties  that  have uses in environmental
restoration  and  preservation  and  processing  of  consumer  products, such as
pharmaceutical,  nutritional  and  health  products.  Specialty end products are
also  manufactured  as  byproducts  with unique growth enrichment properties for
wide agricultural use.  DuroZyme plants provide a comprehensive solution that is
unique,  stable  and  natural.

The  DuroZyme  process  is a 100% natural process that is provided by way of the
exclusive  3SF  Technology  in  environmentally-friendly  DuroZyme  plants.  The
fermentation  is  carried  out  under  aerobic conditions, at high temperatures,
using  natural  organic  substrates  and  using  naturally  occurring  heat- and
oxygen-loving  microorganisms.  The  high  temperatures  pasteurize  the  input
organic  material  and  destroy  pathogens  and  other  undesirable  organisms,
including insects, insect eggs, larvae and worms.  The aerobic conditions of the
fermentation  control  obnoxious  odors.  The  full  range  of  heat-loving
microorganisms  naturally  occurring on the input organic materials are provided
with  their  natural  food  sources.

The  3SF  Technology  is  not  limited  by  the  unique  growth  or fermentation
conditions  of  a  specific  microorganism  like  other  commercial fermentation
technologies  used  to produce enzymes.  The microorganisms used in the DuroZyme
process  are  not  modified  or  manipulated  in any way.  No microorganisms are
specifically  added,  and  no  chemical additives or synthetic media are needed.
The  input  materials,  process  and  products  are  all  natural.

The  selection  of  specific  natural  raw  materials  and application of unique
process  conditions  enable  stable and natural enzymes to be tailor-produced to
meet  the  needs  of any enzyme application.  Unique, stable and natural enzymes
are  obtained  by  separating  solid-liquids  from the fermented organic slurry.
DuroZymes  are  recovered  and  purified  from  the liquid stream using specific
steps.  The DuroZymes and end products are packaged, marketed and distributed to
the  market  from  each  of  the  strategically  located  plants.

The  DuroZyme  process  and  3SF  Technology  have  the  following  attributes:

   -  efficient  -  continuous  production  of  commercial  DuroZymes;
      ---------
   -  aerobic  -  non-odor  producing;
      -------
   -  unique  -  processing  technologies  not  previously  available;
      ------
   -  flexible  and  robust  -  production  of virtually any enzyme type through
      ---------------------
      specific  selection  of  input  raw  material  and  control  of  operating
      conditions;
   -  selective - one type of input raw material yields one major type of stable
      ---------
      enzyme;  and
   -  cost-effective  -  very  high value DuroZyme and end products manufactured
      --------------
      from  low-value raw materials for which a processing fee is collected.


                                        4
<PAGE>
The  Company  has  plans  to  build a prototype DuroZyme plant in Langley, B.C.,
Canada,  as a fully integrated manufacturing and technology development facility
capable  of  processing  up  to  60  tons  per day of specific, selected organic
material.  The  cost  of  the  prototype  plant  is  estimated  at  $10 million.

The  DuroZyme  plant
--------------------

The  DuroZyme  plant  is a state-of-the-art modular-built facility that utilizes
the  3SF  Technology  and  DuroZyme  process.  The  highly  engineered  plant is
designed  to  be  a  stand-alone  production facility.  Each plant takes up very
little  space,  about 10,000 square feet.  A plant can be sited in or near urban
or  residential areas since it is operated with zero environmental impact.  This
is  assured with use of an advanced air handling and water recovery system.  The
spent  air  is passed through a scrubber system to remove particulates before it
is  burnt  off  or thermally oxidized by the power co-generator.  Operating from
its  own  power generator, each plant offers a self-sustaining high-temperature,
aerobic  fermentation  system  that  is  not  dependent  on  utility  power.

Duro  Enzyme  plans  to strategically site DuroZyme plants throughout the world.
Construction  of  plants  is  planned  to be at a rate of one per year and at an
estimated cost of $8 million using debt financing.  A total of five wholly owned
DuroZyme  plants  are  projected  within  the  first  five  years of operations.

Marketplace  and  the  Duro  Enzyme  Solution
---------------------------------------------

In  1998, the global industrial enzyme market was estimated to be worth about $2
billion.  The addition of medicinal, pharmaceutical, health, dietary product and
other  consumer  markets  in  which  enzymes  were used has increased the global
enzyme  market  to  just  over $3 billion.  The market is expected to grow to $6
billion  within the next few years.(1) Despite the large number of applications,
the  global  enzyme  market  represents  a  virgin market in terms of its value.
Applications  have  been limited to the properties of available enzyme products.
This  has  limited  market  expansion  and  growth.  The introduction of the 3SF
Technology  provides  a  wider  range  of  applications  for  enzyme  use in the
production  of  products  and  does  so  efficiently  and  naturally.

Duro  Enzyme believes the DuroZyme plants provide specific generators of organic
materials  with a cost-effective and efficient way to manage these materials and
divert  them  from the disposal chain.  Duro Enzyme will work with generators to
supply  specific,  high-quality  single  source  or  "pure" organic materials of
consistent  composition  and  volume.  These  materials  may  be  in the form of
liquids  or  solids  and  from  sources  including  the  following:

     -     food  processors
               -  fish  and  fish  process  byproducts
               -  processed  fruit  and  vegetable  byproducts
               -  meat  trimmings  and  byproducts
               -  cheese  whey  and  other  dairy  byproducts
               -  grain  and  cereal  byproducts
               -  fruit  juices,  jams  and  their  byproducts
               -  brewery  byproducts
               -  winery  byproducts

     -   supermarkets,  other  food  retailers  and  restaurants
               -  fresh  produce
               -  meat  trimmings  and  bones
               -  fish  and  fish  products
               -  cereal  products  and  baked  goods
               -  fryer  oils  and  greases
               -  coffee  grounds  and  filters

---------------------
(1)  Scientists Find Jobs Turning "Extremozymes' Into Industrial Catalysts.  The
Scientist,  Vol.  10,  No.  19,  pp.  1-8  (1996);  Enzymes  Usher in a New Era.
Chemical  Engineering  (July  1998);  A  Global  Business  Report  on  Enzymes
(Industrial,  Food  & Research).  Global Industry Analysts Inc., p.  750 (1997);
U.S.  Commercial  Enzyme  Markets.  Frost & Sullivan Publishers, p.  275 (1998);
---------------------------------
Enzymes  for  Industrial Applications: Products, Uses, Technologies and Economic
Values.  Publications  Resource  Group,  p.  290  (1998); M.T.  and B.L.  Marrs,
Extremophiles.  Scientific  American,  p.  8  (April  1997).


                                        5
<PAGE>
     -   industrial  processors
               -  pulp  and  paper  byproducts
               -  tannery  residuals
               -  oil  refining  byproducts
               -  fermentation  byproducts

     -     miscellaneous  sources
               -  paper  and  cardboard
               -  corn  stalk,  straw  and  other  plant  biomass

The Company believes that high quality "pure" organics are plentiful and readily
available  to  DuroZyme  plants,  especially in urban areas where management and
disposal  of  organic  waste  and  associated  environmental  problems  require
solutions  such  as  DuroZyme  processing.

The availability of unique, stable and natural enzyme products from the DuroZyme
process  opens  untapped  markets.  DuroZymes  demand  a  premium  price  in the
marketplace because they expand enzyme application by being stable and available
for  a wider range of uses that usually destroy other enzymes.  Other commercial
enzymes  range  in  price  from  $500.00  per ounce to more than $250,000.00 per
ounce.  DuroZymes  open  up  enzyme  markets  by  providing  applications  not
previously available.  Some of the products developed using the DuroZyme process
are  the  following:  pharmaceuticals;  health  products;  cosmetics; analytical
tests;  diagnostic  tests;  home and commercial test kits; industrial processes,
including  pulp  and  paper  manufacture,  leather  tanning  and  ethanol  fuel
production;  food  products;  food  production  processes;  animal  feeds;  soil
remediation;  water  purification;  organic  waste  reduction; and bioconversion
technologies.

DuroZymes  manufactured at the Company's prototype DuroZyme plant will initially
target  the  animal feed industry.  A large number of different enzymes are used
to increase feed quality, provide conversion efficiencies and increase the value
and  utilization  of  traditionally  low  value feed materials.  Key enzymes are
those that break down cellulose, a major component of straw, hay, corn stalk and
other  plant  biomass  and  those  that  breakdown  specific antinutritional and
intolerance  factors,  including  lignin,  phytates  and  lactose.

The  specialty  end  products  manufactured  by each DuroZyme plant are the bulk
solids  byproduct  of  the  DuroZyme  process.  The  specialty  end products are
enriched with residual DuroZymes not removed in the solids-liquids separation of
the  fermented  organics.  The end products also contain pre-digested solids and
microbial biomass, which are highly stable and available forms of organic matter
and  nutrients.  They  are  valuable  as nutrients and growth enhancers for wide
agricultural  uses,  including  the  following:  specialty fish feeds; specialty
animal  feeds; feed enrichment additives; hydroponic growth media for greenhouse
crop  production; mushroom growth media; specialty plant fertilizers; fertilizer
enrichment  additives;  and  soil  conditioners.  These  and  other applications
provide  vertical  integrated  business  opportunities  to  the main business of
DuroZyme  production.

Competition
-----------

Approximately  70%  of  the  commercial  enzymes  are  products  of  microbial
fermentation.  The  microorganisms  are  specific  bacteria,  fungi  or  yeast,
isolated  from soils, water or other sources.  Isolation and purification of the
microorganisms  is  a  time-consuming  and  resource  intensive  process,  often
involving  trial  and  error  in  the  laboratory and significant expense.  Once
obtained,  the microorganism is usually modified so that it produces the desired
enzyme  in  high yield by using genetic techniques.  The enzymes are cultured in
batches  in  large  fermentation  tanks.

---------------------------
(2)  A  Global  Business Report on Enzymes (Industrial, Food & Research). Global
Industry  Analysts  Inc., p. 750 (1997); U.S. Commercial Enzyme Markets. Frost &
                                         ------------------------------
Sullivan  Publishers,  p.  275  (1998);  Enzymes  for  Industrial  Applications:
Products,  Uses,  Technologies and Economic Values. Publications Resource Group,
p.  290  (1998);  Biochemicals  and  Reagents  for  Life Science Research. SIGMA
                                                                           -----
Product  Catalog,  Sigma-Aldrich Canada Ltd. (1997); Anachemia Sciences Catalog.
      ----------                                     --------------------------
Anachemia  Sciences  Ltd. (1998).
(3)  A  Global  Business  Report  on  Enzymes  (Industrial,  Food  &  Research).
Global  Industry  Analysts  Inc., p. 750 (1997); U.S. Commercial Enzyme Markets.
                                                 ------------------------------
Frost & Sullivan Publishers, p. 275 (1998); Enzymes for Industrial Applications:
Products,  Uses,  Technologies and Economic Values. Publications Resource Group,
p. 290 (1998); Chemistry from Unknown Microbes. Science/Technology, Vol. 77, No.
1 (1999); Stroh, W.H., Trends in Use of Industrial Bioprocessing Enzymes for the
21st  Century, Genetic Engineering News (September 15, 1994).


                                        6
<PAGE>
The Company believes the traditional method of batch fermentation that is relied
upon  by  most  producers  of  commercial  enzymes is limiting.  The limitations
include the following:

-    The microbial  fermentation  method depends upon the use of mild conditions
     to promote  the  growth of the  enzyme-producing  microorganism  that often
     produces an inactive form of enzyme.
-    The action of the enzyme products is greatest towards  synthetic  materials
     but show poor performance in commercial use with natural materials.
-    The genetic  manipulation  of the  microorganisms  or of the  enzymes  they
     produce results in non-natural microorganisms and/or non-natural products.
-    The expense of time, resources and money in the development and manufacture
     of specific enzymes is often  significant  which results in high prices for
     the resulting enzyme products and processes.
-    The  manufacture of enzymes in batches is inefficient and does not meet the
     individual needs of many end-users.

While  a  wide  range  of  commercial enzymes are available, there is a need for
enzymes  with  greater  stability  and  unique properties.  Unique and specialty
enzymes  command  a  premium  price  in  the  marketplace.  The  potential  for
substantial  revenue  has driven the formation of numerous small-scale specialty
enzyme  producers,  as  well  as  the development and increased use of high-tech
genetic  engineering methods to produce enzymes with desired properties.

The  Company  believes the development of the 3SF Technology delivered by way of
turnkey  DuroZyme  plants  is  a  major  advance.  The new technology avoids the
limitations  faced by existing enzyme producers.  The technology does not depend
on  mild  fermentation  conditions  or  on  a  limited  number  of  species  of
microorganisms.  Rather,  natural  food  sources  are  used,  widening  the
applications  for  the  DuroZyme  process.  The  supply of single-source organic
materials  needed  by DuroZyme plants is readily accommodated by the millions of
tons  of  organic  waste  produced  each  year  throughout  the  world.

Research  and  Development
--------------------------

The  Company's  future  success  will  depend  on  its focus of its research and
development  efforts  enhancing  its  existing  products  and  developing  new
applications  based on its innovative technology.  The Company plans to continue
to find new applications for its 3SF Technology.  The Company continues to focus
on  the  various  uses of the enzymes produced in the process to further develop
its  markets  and  products.

Intellectual  Property  Protection
----------------------------------

The  DuroZyme  plant delivery system and exclusive 3SF Technology and commercial
DuroZyme  and  specialty  products  will  be  protected  through  patents  and
trademarks.  The  Company  is  in the process of filing for patent protection of
the  3SF Technology in the United States and Canada.  International filings will
follow.  Confidentiality  policies will be internally implemented to protect the
Company's  proprietary  information.

----------------------------
(4) Thermophilic Organisms as Sources of Thermostable Enzymes, TIBTECH, Vol.  7,
No.  12,  pp.  349-353  (1989); The Enzymes from Extreme Thermophiles: Bacterial
Sources,  Thermostabilities and Engineering / Biotechnology, Vol.  45, p.  57-98
(1992);  Personal Communications with Kerr Anderson of the Dow Chemical Company.

(5)  A  Global Business Report on Enzymes (Industrial, Food & Research).  Global
Industry  Analysts Inc., p.  750 (1997); U.S.  Commercial Enzyme Markets.  Frost
                                         -------------------------------
&  Sullivan  Publishers,  p.  275  (1998);  Enzymes for Industrial Applications:
Products,  Uses, Technologies and Economic Values.  Publications Resource Group,
p.  290  (1998).


                                        7
<PAGE>
Sources  of  Revenue
--------------------

The  Company  anticipates  the  following revenue sources:  technology licensing
fees;  raw  material  processing fees; and end product sales, including specific
DuroZymes,  bulk  growth-enrichment  products  and  DuroZyme  product  blends.

DuroZyme  plants  are  expected  to  be  profitable  within  their first year of
operation.  This  projection  is  based  on  the  following  assumptions:

-    A cost of $8 million to construct the plant.
-    Operating  capacity of up to 60 tons per day,  with the plant  operating at
     90% capacity by the end of the fist year with the  remaining  time allotted
     for startup, commissioning optimization and maintenance.
-    Capital  cost to build a 60 ton per day  DuroZyme  plant is projected to be
     $10 million, not including site development costs.
-    All  plants  are  wholly  owned  and  debt  financed  over 10  years at 10%
     interest.
-    Conservative  estimates project construction of one DuroZyme plant per year
     and a more aggressive estimates project two or more plants per year.
-    Plants are staffed by 12 persons - plant Manager,  Assistant plant Manager,
     Office Clerk/Secretary, six plant Operators and three Control Technicians.
-    Plants  receive  $50 per  ton in  processing  fees,  secured  by  long-term
     put-or-pay  contracts  between the Company and local generators of specific
     organic  materials.  A 60 ton per day plant  operating at capacity 365 days
     per year will generate projected gross revenues of over $1 million per year
     in processing fees.
-    A  single-source  or "pure" organics stream with eight percent total solids
     will yield 4.8 tons of bulk solids  byproduct per day from a 60 ton per day
     DuroZyme plant operating at capacity. This specialty DuroZyme-enriched, end
     product is projected to sell for $500/ton,  yielding  annual gross revenues
     of over $875,000.
-    Every ton of input organic  material  containing eight percent total solids
     is  projected  to yield an ounce of DuroZyme  product  priced at $1,000 per
     ounce.  A 60 ton per day plant  running at capacity  over 365 days per year
     will generate projected annual gross revenues of over $20 million from sale
     of unique, stable and natural DuroZymes.

The  operating  income  depends upon the local tip fee structures, market demand
for end products and specific enzyme product pricing.  Operating costs depend on
a  number  of  factors,  including  local wages, utilities, taxes, finance fees,
logistics  of  obtaining  raw  materials  and  end  product  distribution.

The  Company  projects  completion  of  construction  and  commencement  of full
operation  of  its  prototype  DuroZyme  plant and Technology Development Center
within  its first year of operations.  This facility will showcase Duro Enzyme's
advanced  technology,  delivery  systems  and  products.

Employees
---------

As  of  November  30,  2000,  the  Company  had  seven  consultants.  Of  those
employees,  3  were  classified  as  executive  officers,  two as administrative
personnel,  and  two sales and marketing.  The Company's employees do not belong
to a collective bargaining unit, and the Company is not aware of any labor union
organizing  activity.  The  Company  believes  its future success will depend in
large  part  on  its  continuing  ability  to  attract, train and retain skilled
technical,  sales,  marketing  and  customer  support  personnel.

ITEM  2.  DESCRIPTION  OF  PROPERTY
-----------------------------------

The  corporate  headquarters  of  the  Company  is located at 435 Martin Street,
Blaine Washington, 98230, where it sub-leases approximately 250 square feet at a
monthly  rate  of  US$400.  The Company also has offices at 8412 Armstrong Road,
Langley, British Columbia, V1M 3P5, CANADA.  There it leases approximately 5,000
square  feet  at  a  monthly  rate  of  US$3,000.


                                        8
<PAGE>
The Company believes that these facilities will be suitable for the operation of
its  business for the foreseeable future.  The facilities are adequately insured
against  perils  commonly  covered  by  business  insurance  policies.

ITEM  3.  LEGAL  PROCEEDINGS
----------------------------

The  Company  is  not  presently  a  party  to  any  material  pending  legal or
administrative  proceedings,  and  its  property  is  not  subject  to  any such
proceedings,  except  as  may  be  incurred  in the ordinary course of business.

ITEM  4.  SUBMISSION  OF  MATTERS  TO  A  VOTE  OF  SECURITY  HOLDERS
---------------------------------------------------------------------

No  matters  were  submitted  to  the shareholders during the three month period
ended  September  30,  2000.


                                     PART II

ITEM  5.  MARKET  FOR  COMMON  EQUITY  AND  RELATED  STOCKHOLDER  MATTERS
-------------------------------------------------------------------------

The  Company's  common  stock  is  traded on the Over-the-Counter Bulletin Board
(OTC-BB)  under  the  symbol  "HMWB."  The  following  table sets forth, for the
periods  indicated,  the  range  of  high  and low sales prices of the Company's
common  stock  as  quoted  by various market makers for the period of January 1,
2000  through  September  30,  2000.

       January 1, 2000 to September 30, 2000:          High*          Low*
                                                     -----------------------
               January  to  March                      $5.00           $1.75
               April  to  June                         $4.00           $2.63
               July to September                       $2.62           $1.48

       *The  pricing  information  was  provided  by  Edgar  Filing  System.

On  November 30, 2000, the Company's common stock was held by approximately 1000
shareholders  of record or through nominee or street name accounts with brokers.

The  Company  has  not  paid  dividends  in  prior years and has no plans to pay
dividends  in  the near future.  The Company intends to reinvest its earnings on
the  continued  development  and  operation  of  its  business.  Any  payment of
dividends  would  depend  upon  the  Company's pattern of growth, profitability,
financial  condition,  and such other factors as the Board of Directors may deem
relevant.

RECENT  SALES  OF  UNREGISTERED  SECURITIES

In  February, 2000, the Company conducted a 1.2 to 1 forward stock split whereby
the  holders  of  the  Common  Stock of the Company received 1.2 shares for each
share  of  Common Stock held.  The Company issued 5,479,400 shares of its Common
Stock  to  its  existing  shareholders  in connection with the stock split.  The
offering  was  made pursuant to an exemption from the Securities Act of 1933, as
amended,  namely  Section  3(a)(3)(9)  of  the  Act.


                                        9
<PAGE>
ITEM 6.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
--------------------------------------------------------------------------------
OF  OPERATIONS
--------------

The following discussion of the financial condition and results of operations of
the  Company should be read in conjunction with the financial statements and the
related notes there to included elsewhere in this transitional annual report for
the  nine  months  ended  September  30,  2000.  This transitional annual report
contains  certain  forward-looking statements and the Company's future operating
results  could  differ  materially  from  those  discussed  herein.

INTRODUCTION

The  Company  is a Nevada corporation formed on September 15, 1995.  The Company
has  been  a  development  stage  company  specializing  in  the  wholesaling of
specialty  and  gourmet  cheeses.  The  Company suspended operations in the year
2000.

On October 16, 2000, the Company conducted a voluntary share exchange whereby it
offered  up to 28,800,000 shares of its Common Stock to the shareholders of Duro
Enzyme  Products  Inc.  ("Duro  Enzyme")  in  exchange for all of the issued and
outstanding  shares  of  Duro  Enzyme.  The  effect of the share exchange was to
transfer control of the Company to the shareholders of Duro Enzyme. The majority
of  shares  of  the  Company are now held by former shareholders of Duro Enzyme.
The  Company  effectively  took  control  of  all  of the assets of Duro Enzyme,
including  its  subsidiaries,  by  becoming its sole shareholder.  Following the
share exchange, the Company has offices in both Canada and the United States and
has  changed  the  focus  of  its business from gourmet and specialty cheeses to
recycling  technologies.  Its Canadian office is located adjacent to the site of
its  prototype  DuroZyme  plant  and  Technology  Development Center in Langley,
British  Columbia.

The  Company  now  has the license to utilize and exploit the DuroZyme Plant and
3SF  Technology  anywhere in the world.  Through application of this technology,
the Company can manufacture unique, stable and natural enzymes and specialty end
products.  This technology solves a major environmental problem and provides the
world  with  unique,  stable  and  natural  enzyme  products.

The  Company  will  implement  its  business  plan  through  two  subsidiaries:

     Duro  Enzyme  Solutions  Inc. ("Duro Solutions USA"), a Nevada corporation,
     ----------------------------------------------------
holds  all the licenses and rights to the 3SF Technology and service as the sole
sublicensor of the technology.  Duro Solutions USA provides technical support to
the  DuroZyme  Plants,  including  quality  control  and assurance functions and
training  in  the  United  States.

     Duro  Enzyme  Solutions  Inc.  ("Duro  Solutions  Canada"),  a  Canadian
     ----------------------------------------------------------
corporation,  is responsible for managing and operating the Company's Technology
Development Center, for carrying out and managing the corporate research and new
product  development,  for protection of intellectual property, and for bringing
new  ideas to commercialization, through research and development contracts with
Thermo  Enzyme  Products  Inc.

STATUS  OF  OPERATIONS

During  the  nine  months ended September 30, 2000 the operations of the Company
were  suspended.  On  October  16,  2000, the Company acquired Duro Enzyme.  The
operations  of  the  Company  after  October  16,  2000  consist entirely of the
business  of  Duro  Enzyme.

The  Company  changed  its  fiscal  year end from December 31 to September 30 by
unanimous  consent  of  the  Board  of  Directors  on  December  15,  2000.

PLAN  OF  OPERATIONS

With  the  acquisition  of  Duro  Enzyme,  the  Company has shifted its business
operations  away from gourmet and specialty cheeses to DuroZyme technology.  The
new business is in the early stages of operations and is focused on implementing
and developing its business plan to meet its growth objectives.  The majority of
the  current  resources  of  the  Company will focus on developing the recycling
technologies  of  Duro  Enzyme.


                                       10
<PAGE>
FINANCIAL  CONDITION  AND  RESULTS  OF  OPERATIONS

Nine  Months  Ended September 30, 2000, Compared to Year Ended December 31, 1999

The  following  discussion  sets  forth  information  for  the nine months ended
September  30,  2000,  compared  with the twelve months ended December 31, 1999.
This  information  has  been  derived  from  audited financial statements of the
Company  and  Duro  Enzyme  contained  elsewhere  in  this  Form  10-KSB.

Results  of  Operations
-----------------------

Planned principal operations of the Company commenced in 1995.  However, to this
date  the  Company  has  received limited revenues.  In June 1975, the Financial
Accounting  Standards  Board,  in  its Statement No. 7, set forth guidelines for
identifying  an  enterprise  in  the  development  stage  and  the  standards of
financial  accounting  and  reporting  applicable to such an enterprise.  In the
opinion of the management of the Company, the Company and Duro Enzyme as well as
their  activities  from  inception  through  September  30, 2000 fall within the
referenced  guidelines.  Accordingly,  the  Company  has  reported  its and Duro
Enzyme's  activities  in  accordance  with  the aforesaid Statement of Financial
Accounting  Standards  No.  7.

Sales  and  Revenues
--------------------

During the nine months ended September 30, 2000 and the years ended December 31,
1999 and 1998, the Company sustained a net loss of approximately $3,799, $29,765
and  $40,521, respectively.  The Company's losses up through September 2000 have
been  due  to  suspended  business  operations.

The  Company intends to derive revenues generally from the implementation of the
Duro Enzyme business plan.  For the ten months (since inception) ended September
30,  2000,  Duro  Enzyme  sustained  a  net  loss  of  $3,932.

Expenses
--------

General  and  administrative  expenses  for the Company were $2,999, $27,454 and
$41,577 for the nine months ended September 30, 2000 and the for the years ended
December  31,  1999  and  1998, respectively.  The significant expenditures have
been  business  startup  costs  and  consulting  fees.

As  the  Company  proceeds  with  the  business plan of Duro Enzyme, the Company
expects  to  incur  significant  startup  costs.  During  the  ten  months ended
September  30,  2000,  Duro  Enzyme  had  expenses of $3,932, which consisted of
$2,699  in  filing  fees and $1,233 in interest.  As of September 30, 2000, Duro
Enzyme  had  incurred limited expenditures but that is expected to change during
the  three  months  ended  December  31,  2000.

LIQUIDITY  AND  CAPITAL  RESOURCES

No  material  commitments  for  capital  expenditures  were made during the nine
months  ended  September  30,  2000.

As  of  September  30,  2000,  the  Company  had  net stockholders' deficit of $
$25,923,  accumulated  losses  during  the development stage of $1,349,077 and a
working  capital  deficit  of $25,938.  As of the same date, Duro Enzyme had net
stockholders'  deficit  of  $3,931  and a working capital deficit of $1,003,931.
There  can  be no assurance that the Company will be able to continue as a going
concern  or  achieve  material  revenues  or  profitable  operations.

The  Company  plans  to utilize a combination of internally generated funds from
operations,  potential  debt and/or equity financings to fund its short-term and
long-term  growth.  The  availability of future financings will depend on market
conditions.  A  portion  of  the  funds may be used to grow the business through
acquisitions  of  other  businesses.


                                       11
<PAGE>
The  forecast  of  the  period  of  time  through  which the Company's financial
resources  will be adequate to support operations is a forward-looking statement
that  involves  risks  and  uncertainties.  The  actual funding requirements may
differ  materially  from this as a result of a number of factors including plans
to  rapidly  expand  its  new  operations.

EFFECT  OF  FLUCTUATIONS  IN  FOREIGN  EXCHANGE  RATES

The Company's current operations are now located outside the United States.  The
functional  currency  for  this  foreign  operation  is the local currency.  The
carrying  value of the Company's investments in Canada is subject to the risk of
foreign  currency  fluctuations.  Any  revenues  received  from  the  Company's
international  operations  will  be  subject  to  foreign  exchange  risk.

RECENT  ACCOUNTING  PRONOUNCEMENTS

In  June  1998,  the  Financial  Accounting  Standards Board issued Statement of
Financial  Standards No. 133, "Accounting for Derivative Instruments and Hedging
Activities"  (SFAS  No.  133).  SFAS No. 133 requires companies to recognize all
derivatives  contracts  as either assets or liabilities in the balance sheet and
to  measure them at fair value.  If certain conditions are met, a derivative may
be  specifically  designated  as a hedge, the objective of which is to match the
timing  of  gain  or  loss  recognition  on  the  hedging  derivative  with  the
recognition  of  (i)  the  changes  in  the  fair  value  of the hedged asset or
liability  that  are attributable to the hedged risk or (ii) the earnings effect
of  the  hedged  forecasted  transaction.  For  a derivative not designated as a
hedging  instrument,  the  gain or loss is recognized in income in the period of
change.  SFAS  No.  133  is  effective  for  all fiscal quarters of fiscal years
beginning  after  June  15,  2000.

Historically,  the  Company has not entered into derivatives contracts either to
hedge existing risks or for speculative purposes.  Accordingly, the Company does
not  expect  adoption  of  the  new  standard  on  January 1, 2001 to affect its
financial  statements.

In  December  1999,  the  SEC  staff released Staff Accounting Bulletin No. 101,
"Revenue  Recognition  in  Financial  Statements" ("SAB 101").  SAB 101 provides
interpretive guidance on the recognition, presentation and disclosure of revenue
in  the  financial  statements.  SAB  101  must  be  applied  to  the  financial
statements  no  later  than  the quarter ending September 30, 2000.  The Company
does not believe that the adoption of SAB 101 will have a material affect on the
Company's  financial  results.

In  March  2000,  the Financial Accounting Standards Board issued Interpretation
No.  44  ("FIN  44")  Accounting  for  Certain  Transactions  Involving  Stock
Compensation,  an  Interpretation  of  APB Opinion No. 25.  FIN 44 clarifies the
application  of  APB  No.  25 for (a) the definition of employee for purposes of
applying  APB  No. 25, (b) the criteria for determining whether a plan qualifies
as  a  non-compensatory  plan,  (c)  the  accounting  consequences  of  various
modifications  to the terms of a previously fixed stock option or award, and (d)
the  accounting  for  an  exchange  of  stock  compensation awards in a business
combination.  FIN  44  is  effective July 2, 2000, but certain conclusions cover
specific  events that occur after either December 15, 1998, or January 12, 2000.
The  Company  will  adopt  FIN  44  in accounting for the stock options granted.

In  March  2000,  EITF  00-2  "Accounting  for  Web  Site Development Costs" was
released.  EITF 00-2 provides guidance on how an entity should account for costs
involved in such areas as planning, developing software to operate the web site,
graphics,  content, and operating expenses.  EITF 00-2 is effective for web site
development  costs  incurred  for fiscal quarters beginning after June 30, 2000.

FORWARD-LOOKING  STATEMENTS

This  Annual  Report  on  Form  10-KSB contains forward-looking statements.  The
words  "anticipate",  "believe",  "expect",  "plan",  "intend",  "estimate",
"project",  "could",  "may",  "foresee"  and similar expressions are intended to
identify  forward-looking  statements.  The following discussion of risks should
be  read  in  conjunction  with the Company's financial statements and notes and
other financial information included elsewhere in this Form 10-KSB.  In addition
to  historical  information,  this  Form 10-KSB contains statements that involve
risks  and  uncertainties.  The Company's actual results could differ materially
from  the  results  discussed  in  the forward-looking statements.  Factors that
could  cause  or  contribute to such differences include those discussed in this
"Risk  Factors"  section  of  the  Form  10-KSB.


                                       12
<PAGE>
RISK  FACTORS

Shareholders  and  prospective  purchasers  of the Company's Common Stock should
carefully  consider  the  following  risk  factors  in  addition  to  the  other
information  appearing  in  this  Transitional  Annual  Report  on  Form 10-KSB.

     THE COMPANY  MAY  REQUIRE  ADDITIONAL  EQUITY  FINANCING,  WHICH MAY NOT BE
     AVAILABLE AND MAY DILUTE THE OWNERSHIP INTERESTS OF INVESTORS.

The  Company's  ultimate  success will depend on its ability to raise additional
capital.  No  commitments  to  provide  additional  funds  have  been  made  by
management  or  other  shareholders.  The  Company  has  not  investigated  the
availability,  source  or  terms that might govern the acquisition of additional
financing.  When  additional capital is needed, there is no assurance that funds
will be available from any source or, if available, that they can be obtained on
terms  acceptable  to  the  Company.  If not available, the Company's operations
could  be  severely  limited,  and  it may not be able to implement its business
plan.  If  equity  financing  is  used  to raise additional working capital, the
ownership  interests  of  existing  shareholders  may  be  diluted.

     THE COMPANY'S OPERATING RESULTS ARE LIKELY TO FLUCTUATE SIGNIFICANTLY.

As a result of the Company's limited operating history following the acquisition
of  Duro  Enzyme and the planned rapid expansion of its business operations, the
Company's  quarterly  and  annual  revenues  and operating results are likely to
fluctuate  from  period  to  period.  For  this  reason,  you should not rely on
period-to-period  comparisons  of the Company's financial results as indications
of  future results.  The Company's future operating results could fall below the
expectations of public market analysts or investors and significantly reduce the
market  price  of  its  common  stock.  Fluctuations  in the Company's operating
results  will  likely  increase  the  volatility  of  its  stock  price.

     THE COMPANY'S  DEPENDENCE ON RELATIONSHIPS  WITH BUSINESSES AND GOVERNMENTS
     OUTSIDE OF THE UNITED STATES INVOLVES RISKS.

The  Company  depends  on  its  ability  to  establish  and  maintain successful
relationships  with  businesses  and  governments  located outside of the United
States.  If  the Company is unable to establish and maintain such relationships,
it will not be able to implement the business plan in its current configuration,
which  will  affect  both its revenue stream and profit potential.  In addition,
the  Company  faces  political  sovereign  risks  of  conducting  international
business,  including  risks  of  changing  economic conditions, which may have a
material  adverse  effect  on  its  ability  to  expand its operations globally.

     POTENTIAL BUSINESS COMBINATIONS COULD BE DIFFICULT TO INTEGRATE AND DISRUPT
     BUSINESS OPERATIONS.

Any  acquisition  of  or business combination with another company could disrupt
the  Company's  ongoing business, distract management and employees and increase
the  Company's expenses.  If another company acquires the Company, it could face
difficulties  in  assimilating  with  that  company's  personnel and operations.
Acquisitions also involve the need for integration into existing administration,
services,  marketing  and  support  efforts.

     THE COMPANY DOES NOT ANTICIPATE PAYING DIVIDENDS TO COMMON  SHAREHOLDERS IN
     THE FORESEEABLE  FUTURE,  WHICH MAKES INVESTMENT IN THE COMPANY SPECULATIVE
     OR RISKY.

The  Company  has not paid dividends on its common stock and does not anticipate
paying  dividends  on  its  common stock in the foreseeable future. The Board of
Directors  has  sole  authority  to  declare  dividends payable to the Company's
shareholders.  The  fact  that  the  Company  has  not  and does not plan to pay
dividends  indicates  that  the  Company  must use all of its funds generated by
operations for reinvestment in its operating activities and also emphasizes that
the  Company  may not continue as a going concern.  Investors also must evaluate
an  investment  in the Company solely on the basis of anticipated capital gains.


                                       13
<PAGE>
     THE  COMPANY  MAY BE UNABLE TO PROTECT  ITS  INTELLECTUAL  PROPERTY,  TRADE
     SECRETS AND KNOW-HOW  WHICH WOULD REMOVE A BARRIER TO  COMPETITION  AND MAY
     DIRECTLY AFFECT THE AMOUNT OF REVENUE IT GENERATES.

The  Company  depends heavily on its 3SF technology to produce stable and unique
enzymes.  The  Company  is  dependent  on  its ability to keep trade secrets and
obtain  patents  on  business processes as well as on its ability to develop new
processes to meet the needs of its marketplace.  Although the Company intends to
employ  various  methods,  including  trademarks,  patents,  copyrights  and
confidentiality  agreements  with  employees,  consultants  and  third  party
businesses, to protect its intellectual property and trade secrets, there can be
no  assurance that it will be able to maintain the confidentiality of any of its
proprietary  technology,  know-how  or  trade  secrets,  or that others will not
independently  develop  substantially  equivalent  technology.  The  failure  or
inability  to  protect  these rights could have a material adverse effect on the
Company's  operations.

     THE COMPANY MAY NOT BE ABLE TO  EFFECTIVELY  MANAGE ITS GROWTH  WHICH COULD
     HAVE A MATERIAL EFFECT ON ITS BUSINESS OPERATIONS.

The  Company's  ability to manage its growth depends in part upon its ability to
develop and expand operating, management, information and financial systems, and
production  capacity,  which  may  significantly  increase  its future operating
expenses.  No  assurance can be given that it will grow in the future or that it
will  be  able  to  effectively manage such growth.  Its inability to manage its
growth  successfully  could  have  a  material  adverse  effect on its business,
financial  condition and results of operations.  The Company cannot successfully
implement its business model if it fails to manage its growth. The Company plans
to  rapidly  and  significantly  expanded  its  operations  domestically  and
internationally  and  anticipates  further expansion to take advantage of market
opportunities.

     THE COMPANY MAY ENTER INTO NEW LINES OF BUSINESS  WHICH  INVESTORS  ARE NOT
     GIVEN THE OPPORTUNITY TO EVALUATE

In  the  event  of a business combination, acquisition, or change in shareholder
control, the Company may enter into a new line of business which an investor did
not  anticipate  and  in  which  that investor may not want to participate.  The
Company  may make investments in or acquire complementary products, technologies
and businesses, or businesses completely unrelated to its current business plan.
Similarly, an asset acquisition or business combination would likely include the
issuance of a significant amount of the Company's common stock, which may result
in  a  majority  of  the  voting  power being transferred to new investors.  New
investors  may  replace the Company's management.  New management may decide not
to  continue to implement the Company's current business plan, and may decide to
enter into a business completely unrelated to the current business plan which an
investor  did  not  anticipate  and  in  which  that  investor  may  not want to
participate.  In  such  case,  an investor could lose its entire investment on a
business  decision  it  did  not get to evaluate at the time of investing in the
Company.

ITEM  7.  FINANCIAL  STATEMENTS
-------------------------------

Financial  statements  and  supplementary  data  are set forth on pages F-1 thru
F-20.

ITEM  8.  CHANGES  IN  AND  DISAGREEMENTS  WITH  ACCOUNTANTS  ON  ACCOUNTING AND
--------------------------------------------------------------------------------
FINANCIAL  DISCLOSURE
---------------------

None.


                                       14
<PAGE>
                                    PART III

ITEM  9.  DIRECTORS,  EXECUTIVE  OFFICERS,  PROMOTERS  AND  CONTROL  PERSONS;
-----------------------------------------------------------------------------
COMPLIANCE  WITH  SECTION  16(A)  OF  THE  EXCHANGE  ACT
--------------------------------------------------------

In anticipation of the Exchange, on September 29, 2000 the Board of Directors of
the Company accepted the resignation of its directors and executive officers and
appointed  new  directors  and  executive  officers.

The  following  individuals  resigned as directors and executive officers of the
Company:

          Dennis  Davis              Director  and  President
          Cornelia  Davis            Director,  Secretary  and  Treasurer
          Florence  Roberts          Director

The following individuals were appointed directors and executive officers of the
Company:

          Robert  L.  Jackman        Director,  President  and  Treasurer
          Dean  Branconnier          Director  and  Vice  President
          Jolene  Fuller             Director  and  Secretary

The  following  table sets forth the name, age and position of each Director and
Executive  Officer  of  the  Company  and  Duro Enzyme as of September 30, 2000.

<TABLE>
<CAPTION>
NAME               AGE  POSITION
-----------------  ---  --------
<S>                <C>  <C>
Rowland Wallenius   30  President, Secretary, Treasurer and sole Director of Duro
                        Enzyme

Robert L. Jackman   38  President, Treasurer and a Director of Home.Web

Dean Branconnier    32  Vice President and a Director of Home.Web

Jolene Fuller       25  Secretary and a Director of Home.Web
</TABLE>


ROWLAND  WALLENIUS  -  PRESIDENT, SECRETARY, TREASURER AND SOLE DIRECTOR OF DURO
--------------------------------------------------------------------------------
ENZYME
------
Mr.  Wallenius  has  been  involved  with  Duro  Enzymes Products Inc. since its
inception  and  was  appointed  director  and  elected  President, Secretary and
Treasurer  of  Duro  Enzyme on December 1, 1999. His duties and responsibilities
have  been  to structure and design the initial startup, develop and implement a
business  and  marketing  plan,  negotiate  license  agreements  for  the  core
technology  and  manage  the  daily operations of Duro Enzyme.  Mr. Wallenius is
also President of Planet Earth Recycling Inc., a U.S. public corporation trading
on  the  OTC  Bulletin Board, which is involved in building plants and providing
services  that  involve  waste recycling.  In 1997, Mr. Wallenius formed Rowland
Consulting Ltd., a private consulting company.  He has performed consulting work
for  Thermo  Tech  Technologies  Inc.,  a public Canadian corporation.  Prior to
opening  a  consulting  business, Mr. Wallenius worked as a Chartered Accountant
for  BDO  Dunwoody and Collins Barrow in Vancouver, B.C., Canada.  Mr. Wallenius
received  a Bachelors of Business Administration degree in Accounting from Simon
Fraser  University,  Burnaby,  B.C.,  Canada  in  1993  and  became  a Chartered
Accountant  in  1996.


                                       15
<PAGE>
ROBERT  L.  JACKMAN  -  PRESIDENT,  TREASURER  AND  A  DIRECTOR  OF  HOME.WEB
-----------------------------------------------------------------------------
Prior  to becoming a member of the Board and President of Home.Web, Inc., Robert
Jackman  assisted  with  starting  and  organizing  Duro Enzyme.  Currently, Dr.
Jackman is a research and development and management consultant to Thermo Enzyme
Products  Inc.  (since  1998),  Earthscape Maintenance Inc. (since 1997), Thermo
Tech  Technologies  Inc.  (since  1995),  and  Thermo Tech Research Systems Inc.
(since  1995).  As  a consultant, he has assisted in the management of corporate
research  and  new  product and technology development, coordinated experimental
research projects, provided technical support services, assisted with day-to-day
management  of  operations,  assisted  with promotion of the companies and their
products, assisted with preparation of patent applications, and provided quality
control  of  facilities.  In  1994  and  1995,  Dr. Jackman worked as a research
associate at the University of Guelph in Guelph, Ontario, Canada.  As a research
associate, he conducted research studies on food texture-structure relationships
and  published  his findings.  Dr. Jackman is an author of six book chapters and
20  scientific research papers.  He received a Ph.D. in Food Science in 1992 and
a  Masters of Science degree in 1988 from the University of Guelph.  He also has
a  Bachelors of Science degree from the University of British Columbia, which he
received  in  1985.

DEAN  BRANCONNIER  -  VICE  PRESIDENT  AND  A  DIRECTOR  OF  HOME.WEB
---------------------------------------------------------------------
Over  the  past  year,  Dean  Branconnier has assisted with the organization and
development  of  Duro Enzyme.  Prior to the year 2000, Mr. Branconnier was Plant
Manager  for  the  Richmond Bio Conversion Inc. Thermo Master Plant in Richmond,
British  Columbia,  Canada  (1998-2000) and for the Hamilton Bio Conversion Inc.
Thermo Master Plant in Hamilton, Ontario, Canada (1995-1998).  As Plant Manager,
Mr.  Branconnier  has  the  following  duties and responsibilities:  assist with
project  schedules  and  construction  contracts;  responsible  for  start  of
operations  at  both plants; maintain a daily log of all plant events and manage
daily operations; oversee all office administration; manage expenditures; ensure
compliance with permits; conduct performance reviews of employees;  ensure plant
safety  and  security; and staff the plants.  From 1985 to 1995, Mr. Branconnier
worked  as a management consultant for Thermo Tech Waste Systems Inc., assisting
with  managing  and  organization  the  startup  company.

JOLENE  FULLER  -  SECRETARY  AND  A  DIRECTOR  OF  HOME.WEB
------------------------------------------------------------
Over  the  past  year,  Jolene Fuller has assisted with day-to-day operations at
Duro  Enzyme.  She has monitored the research and development projects, reviewed
promotional  materials,  set up the office and hired personnel.  Since 1998, Ms.
Fuller  was  an  office administrator at Thermo Enzyme Products Ltd.  Her duties
and  responsibilities  included:  hiring  and  training  administrative  staff;
monitoring  research  and  development  projects;  implementing  policies  and
procedures;  and  reviewing  promotional  materials.  Since 1993, Ms. Fuller has
been property manager of several rental properties.  As property manager, she is
responsible  for  collecting rents, monitoring repairs, retaining contracts, and
managing  the  portfolio  of  properties.  Since  1997, Ms. Fuller has been Vice
President  of  Earthscape  Maintenance  Inc.,  a  Langley, B.C. company.  She is
responsible  for office management and bookkeeping and maintaining a database of
customers.  From  1988  to  1998,  Ms.  Fuller was Office Manager at Thermo Tech
Technologies  Inc.  As  Office  Manager  she  had  the  following  duties  and
responsibilities:  bookkeeping;  reviewing  and  filing  documents;  ordering
supplies;  monitoring stock trading activities; preparing promotional materials;
preparing  company  database;  and  managing  staff  of  ten.

COMPLIANCE  WITH  SECTION  16(A)  OF  THE  EXCHANGE  ACT

Directors  and  officers  of  the  Company  are required by Section 16(a) of the
Securities  Exchange  Act  of  1934  to  report  to  the Securities and Exchange
Commission  their  transactions  in,  and beneficial ownership of, the Company's
common  stock, including any grants of options to purchase common stock.  To the
best  of  the  Company's  knowledge,  Dennis  Davis, Cornelia Davis and Florence
Roberts  have  not  filed Form 3 and have not reported any other transactions on
Form  4  or  Form  5  prior to September 30, 2000.  Mr. Davis, Ms. Davis and Ms.
Roberts were  replaced as officers and directors of the Company on September 29,
2000 by Robert L. Jackman, Dean Branconnier and Jolene Fuller.  Mr. Jackman, Mr.
Branconnier  and  Ms. Fuller have filed with the SEC Forms 3 and 4.  These forms
were  filed  after  their  due  dates.


                                       16
<PAGE>
ITEM  10.  EXECUTIVE  COMPENSATION
----------------------------------

The  following  table  sets  forth the compensation we have paid to Dennis Davis
(President  and  Treasurer) for the nine months ended September 30, 2000 and the
fiscal  years  ended  December  31,  1999 and 1998.  No other executive officers
received  more than $100,000 during each of those periods.  The Company does not
currently  have  a  long term compensation plan and does not grant any long term
compensation to its executive officers or employees . The table does not reflect
certain  personal  benefits, which in the aggregate are less than ten percent of
each  Named  Executive  Officer's  salary  and bonus.  No other compensation was
granted  for  the  periods  covered.

<TABLE>
<CAPTION>
                                      SUMMARY COMPENSATION TABLE

                                                              Long Term Compensation
                                                       ----------------------------------
                            Annual  Compensation               Awards            Payouts
                   ----------------------------------  ------------------------  --------
                                                                    Securities
Name                                         Other     Restricted   Underlying
and                                          Annual       Stock      Options/      LTIP     All Other
Principal                                   Compens-    Award(s)     SARs (#)    Payouts     Compen-
Position     Year  Salary ($)   Bonus ($)  ation ($)       ($)          (1)        ($)     sation ($)
-----------  ----  -----------  ---------  ----------  -----------  -----------  --------  -----------
<S>          <C>   <C>          <C>        <C>         <C>          <C>          <C>       <C>
Davis,       2000  $       Nil  N/A        $        0  N/A                   0   N/A       $         0
Dennis       1999  $       Nil  N/A        $        0  N/A                   0   N/A       $         0
(President)  1998  $       Nil  N/A        $        0  N/A             250,000   N/A       $         0
-----------  ----  -----------  ---------  ----------  -----------  -----------  --------  -----------
</TABLE>

(1)  Consists  of grants of stock options under the Company's Stock Option Plan.
The  250,000 stock options granted to Dennis Davis in 1998 were cancelled by him
on  September  27,  2000.

COMPENSATION  OF  DIRECTORS

Directors  are not compensated for their service as directors. All directors are
reimbursed  for  any  reasonable  expenses  incurred in the course of fulfilling
their  duties  as  a  director  of  the  Company.

EMPLOYMENT  CONTRACTS

The  Company  does  not  currently have employment agreements with its executive
officers.

ITEM  11.  SECURITY  OWNERSHIP  OF  CERTAIN  BENEFICIAL  OWNERS  AND  MANAGEMENT
--------------------------------------------------------------------------------

The following table sets forth as of November 30, 2000 certain information known
to the Company regarding the beneficial ownership of the Company's common stock,
and as adjusted to reflect the share ownership for (i) each executive officer or
director  of  the  Company  who  beneficially owns shares; (ii) each shareholder
known to the Company to beneficially own five percent or more of the outstanding
shares of its common stock; and  (iii) all executive officers and directors as a
group.  The  Company  believes  that  the  beneficial owners of the common stock
listed  below,  based  on  information  furnished  by  such  owners,  have  sole
investment  and  voting  power with respect to such shares, subject to community
property  laws  where  applicable.  The  individuals  listed  in  the  table are
accessible  at  the  following  address:  435 Martin Street, Blaine, Washington,
98230.

<TABLE>
<CAPTION>
                                                                             PERCENTAGE OF
NAME AND POSITION                                       NUMBER OF SHARES  OUTSTANDING SHARES
------------------------------------------------------  ----------------  -------------------
<S>                                                     <C>               <C>
Robert L. Jackman - President, Treasurer and Director          1,500,000                 4.6%
------------------------------------------------------  ----------------  -------------------
Dean Branconnier - Vice President and Director                 1,600,000                 4.9%
------------------------------------------------------  ----------------  -------------------
Jolene Fuller - Secretary and Director                         1,625,000                 4.9%
------------------------------------------------------  ----------------  -------------------
ALL CURRENT DIRECTORS AND
OFFICERS AS A GROUP (3 Persons)                                4,725,000                14.4%
------------------------------------------------------  ----------------  -------------------
</TABLE>


                                       17
<PAGE>
CHANGE  IN  CONTROL

The  Company  is  not  aware  of  any  arrangement  that would upset the control
mechanisms  currently  in  place.  Although it is conceivable that a third party
could  attempt  a  hostile takeover of the Company, the Company has not received
notice  of  any  such  effort.

ITEM  12.  CERTAIN  RELATIONSHIPS  AND  RELATED  TRANSACTIONS
-------------------------------------------------------------

None.

ITEM  13.  EXHIBITS  AND  REPORTS  ON  FORM  8-K
------------------------------------------------

<TABLE>
<CAPTION>
EXHIBITS


EXHIBIT
NUMBER   DESCRIPTION
-------  -----------
<C>      <S>

2.1****  Agreement and Plan of Reorganization, executed August 1, 2000, by and between
         Home.Web, Inc. and Duro Enzyme Products Inc.

   3.1*  Articles of Incorporation dated September 12, 1995

  3.2**  Certificate of Amendment of Articles of Incorporation dated July 15, 1998

   3.3*  Bylaws dated June 1, 1997

    4.1  Specimen Stock Certificate for Shares of Common Stock of the Company

10.1***  License and Distribution Agreement between Thermo Enzyme Products Inc. and Duro
         Enzyme Solutions Inc. (U.S.)September 21, 2000

10.2***  Research and Development Services Agreement - Canada between Thermo Enzyme
         Products Inc. and Duro Enzyme Solutions Inc. Canada dated September 21, 2000

10.3***  Research and Development Services Agreement United States between Thermo Enzyme
         Products Inc. and Duro Enzyme Solutions Inc. (U.S.) and Duro Enzyme Products Inc.
         dated September 21, 2000

   23.1  Consent of Hawkins Accounting, Independent Auditor

   27.1  Financial Data Schedule
</TABLE>


*  Filed  on  March  17,  1999,  as  an Exhibit to an amendment to the Company's
Registration  Statement on Form 10-SB and incorporated herein by this reference.

**  Filed  on  June  14,  1999,  as  an Exhibit to an amendment to the Company's
Registration  Statement on Form 10-SB and incorporated herein by this reference.

***  Filed  on  November 20, 2000, as an Exhibit to the Company's Report on Form
10-QSB  for the three months ended September 30, 2000 and incorporated herein by
this  reference.

****  Filed on December 29, 2000, as an Exhibit to a report by the Company on an
amendment  to  Form  8-K  dated  October  16,  2000.


                                       18
<PAGE>
REPORTS  ON  FORM  8-K

No  reports  on  Form 8-K were filed by the Company during the nine months ended
September  30,  2000.

An  amendment to a report on Form 8-K dated October 16, 2000 was filed, however,
on  December  29, 2000.  The amended Form 8-K discusses the change in control of
the  Company  and  the  acquisition  of Duro Enzyme and all of its assets by the
Company  through  a  voluntary  share  exchange with Duro Enzyme's shareholders.
Audited  financial statements of Duro Enzyme and Pro Forma financial information
was  included  in  the  amended  Form  8-K.


                                       19
<PAGE>
SIGNATURES
----------

In  accordance  with  Section  13  or  15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

             HOME.WEB,  INC.

             By:   /s/  Bob Jackman
                ------------------------------
                Robert  L.  Jackman
                President

             Date:   December  29,  2000
                  ----------------------------


In  accordance  with  the Exchange Act, this report has been signed below by the
following  persons  on behalf of the registrant and in the capacities and on the
dates  indicated.

             By:   /s/  Bob. Jackman                Date:  December 29, 2000
                ------------------------                 -------------------
                Robert  L.  Jackman
                President, Treasurer and a Director


             By:   /s/  Dean  Branconnier           Date:  December 29, 2000
                ------------------------                 -------------------
                Dean  Branconnier
                Vice President and a Director


             By:   /s/  Chad  Burback               Date:  December 29, 2000
                ------------------------                 -------------------
                Jolene  Fuller
                Secretary and a Director


                                       20
<PAGE>
<TABLE>
<CAPTION>
                                     INDEX TO FINANCIAL STATEMENTS

                                             HOME.WEB, INC.

<S>                                                                                                <C>
Independent Auditor's Report, dated December 15, 2000 . . . . . . . . . . . . . . . . . . . . . .  F-1

Balance Sheets as at September 30, 2000 and December 31, 1999 (audited) . . . . . . . . . . . . .  F-2

Statement of Operations for the nine months ended September 30, 2000 and
the year ended December 31, 1999 (audited). . . . . . . . . . . . . . . . . . . . . . . . . . . .  F-3

Statement of Cash Flows for the nine months ended September 30, 2000 and
the year ended December 31, 1999 (audited). . . . . . . . . . . . . . . . . . . . . . . . . . . .  F-4

Statement of Shareholders' Equity as at September 30, 2000 and December 31, 1999 (audited). . . .  F-5

Summary of Significant Accounting Policies. . . . . . . . . . . . . . . . . . . . . . . . . . . .  F-6

Notes to Financial Statements (audited) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  F-7


                                      DURO ENZYME PRODUCTS INC.

Independent Auditors' Report, dated October 17, 2000. . . . . . . . . . . . . . . . . . . . . . .  F-11

Consolidated Balance Sheet as at September 30, 2000 (audited) . . . . . . . . . . . . . . . . . .  F-12

Consolidated Statement of Loss for the ten months ended September 30, 2000 (audited). . . . . . .  F-13

Consolidated Statement of Changes in Financial Position for the ten months ended
September 30, 2000 (audited). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  F-14

Notes to Financial Statements for the ten months ended September 30, 2000 (audited) . . . . . . .  F-15


                   INDEX TO PRO FORMA FINANCIAL STATEMENTS OF THE COMBINED ENTITY

Pro Forma Consolidated Balance Sheet as at September 30, 2000 (unaudited) . . . . . . . . . . . .  F-18

Pro Forma Consolidated Statement of Loss for the nine months ended September 30, 2000 (unaudited)  F-19

Pro Forma Consolidated Statement of Loss for the year ended December 31, 1999 (unaudited) . . . .  F-20
</TABLE>


<PAGE>
To  the  Board  of  Directors  and  Shareholders
------------------------------------------------
Home  Web,  Incorporated
Monterey,  California

                          INDEPENDENT AUDITOR'S REPORT
                          ----------------------------

I  have audited the balance sheet of Home Web, Incorporated (a development stage
company)  as  of  September  30,  2000  and  December  31,  1999 and the related
statements of operations, stockholders' equity and cash flows for the nine month
period  ended  September  30,  2000  (Note  D) and the twelve month period ended
December  31,  2000.  These  financial  statements are the responsibility of the
Company's  management.  My  responsibility  is  to  express  an opinion on these
financial  statements  based  on  my  audit.

I  conducted  my audit in accordance with generally accepted auditing standards.
Those  standards  require that I plan and perform the audit to obtain reasonable
assurance  about  whether  the  financial  statements  are  free  of  material
misstatement.  An audit includes examining, on a test basis, evidence supporting
the  amounts  and  assessing  the  accounting  principles  used  and significant
estimates  made  by  management,  as  well  as  evaluating the overall financial
statement  presentation.  I  believe that my audit provides reasonable basis for
my  opinion.

In  my  opinion,  the  financial  statements  referred to in the first paragraph
present  fairly,  in  all material respects, the financial position of Home Web,
Incorporated,  as  of  September  30,  2000 and December 31, 1999 the results of
operations  the  cash  flows  and  the  cumulative  results  of  operations  and
cumulative  cash  flows  for  the  year  then ended in conformity with generally
accepted  accounting  principles.

The  accompanying  financial  statements have been prepared assuming the Company
will  continue  as  a  going  concern.  As  discussed in Note I to the financial
statements,  the  Company  has  incurred net losses since inception, which raise
substantial  doubt  about  its  ability  to  continue  as  a going concern.  The
financial  statements  do  not include any adjustment that might result from the
outcome  of  this  uncertainty.



                                   /s/  "Hawkins  Accounting"



December  15,  2000


                                      F - 1
<PAGE>
<TABLE>
<CAPTION>
                             HOME WEB, INCORPORATED
                          (A Development Stage Company)
                                 BALANCE SHEET
                   September 30, 2000 and December 31, 1999
                                   (Audited)

ASSETS
                                                 2000          1999
                                                 ----          ----
<S>                                             <C>           <C>
Current assets
  Cash in bank                                  $         0   $         7
  Non-trade receivable                                1,450         1,450
                                                ------------  ------------
    Total current assets                              1,450         1,457

Equipment
  Coolers and equipment                              40,308        40,308
  Office equipment                                    9,841         9,841
                                                ------------  ------------
                                                     50,149        50,149
  Accumulated depreciation                           (9,288)       (9,288)
                                                ------------  ------------
    Total equipment                                  40,861        40,861

Other assets
  Trade name                                         11,000        11,000
                                                ------------  ------------
    Total other assets                               11,000        11,000
                                                ------------  ------------

    TOTAL ASSETS                                $    53,311   $    53,318
                                                ============  ============

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
  Accounts payable                                    1,426   $    17,655
  California Franchise Tax payable                        0         3,116
  Loan from affiliate                                25,962         2,825
                                                ------------  ------------
    Total current liabilities                        27,388        23,596

Shareholders' equity
  Capital stock                                      27,507        27,507
  Paid in capital                                 1,347,493     1,347,493
  Deficit accumulated during development stage   (1,349,077)   (1,345,278)
                                                ------------  ------------
    Total shareholders' equity                       25,923        29,722
                                                ------------  ------------

  TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY    $    53,311   $    53,318
                                                ============  ============
</TABLE>

    The accompanying notes are an integral part of the financial statements.


                                     F - 2
<PAGE>
<TABLE>
<CAPTION>
                             HOME WEB, INCORPORATED
                          (A Development Stage Company)
                             STATEMENT OF OPERATIONS
     For the nine months ended September 30, 2000 and the twelve months ended
                                December 31, 1999
                                   (Audited)

                                                                        September 30,2000
                                                                             Deficit
                                                                           Accumulated
                                                                             During
                                        Nine Months       Twelve Months    Development
                                           2000               1999            Stage
                                    -------------------  ---------------  -------------
<S>                                 <C>                  <C>              <C>
Sales                               $                0   $          528   $     18,887
Cost of Sales                                        0              523         15,091
                                    -------------------  ---------------  -------------
Gross Margin                                                          5          3,796
Expenses
  Advertising                                                         7            856
  Amortization                                                                   1,584
  Consulting fees                                2,929            5,500         14,125
  Equipment rental                                                               2,339
  Depreciation                                                    4,003          9,288
  Licenses and taxes                                                145            370
  Office help                                                     1,591         12,432
  Office supplies                                   70              588          3,830
  Postage                                                                          673
  Travel, meals and entertainment                                    54          2,679
  Rent, utilities and telephone                                     248          3,591
  Organization and start up costs                                15,318         41,674
  Compensation due stock issuance                                            1,254,500
                                    -------------------  ---------------  -------------
    Total expenses                               2,999           27,454      1,347,941
                                    -------------------  ---------------  -------------
    (Loss) from operations                      (2,999)         (27,449)    (1,344,145)
Other income (expense)
  Interest                                                                          50
  Nondeductible penalties                                           716            882
  State tax expense                                800            1,600          4,000
                                    -------------------  ---------------  -------------
    Total other expenses                           800            2,316          4,932
                                    -------------------  ---------------  -------------
    Net loss                        $           (3,799)  $      (29,765)  $ (1,349,077)
                                    ===================  ===============  =============
Loss per share
  of common stock                   $          (0.0001)  $      (0.0010)  $    (0.0410)
Weighted average of
  shares outstanding                        32,876,400       27,157,000     32,876,400
                                    ===================  ===============  =============
</TABLE>

    The accompanying notes are an integral part of the financial statements.


                                     F - 3
<PAGE>
<TABLE>
<CAPTION>
                             HOME WEB, INCORPORATED
                          (A Development Stage Company)
                     STATEMENT OF CASHFLOWS-INDIRECT METHOD
     For the nine months ended September 30, 2000 and the twelve months ended
                                December 31, 1999
                                   (Audited)

                                                                        September 30, 2000
                                                                            Cash flows
                                                                            Accumulated
                                                                              During
                                                Nine Months  Twelve Months  Development
                                                    2000        1999          Stage
                                                   ----------  -----------  ------------
<S>                                                 <C>        <C>          <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)                                   $ (3,799)  $  (29,765)  $(1,349,077)
Adjustments to reconcile net income to net cash
  provided by operating activities
  Depreciation and amortization                                     4,003         9,288
  Stock issued for services                                           500     1,254,500
  Expensing of organization costs                                   2,376         2,366
  Increase in accounts payable                                     17,655           500
  Increase in accounts receivable                                                (1,450)
  Increase in accrued liabilities                      3,792        5,141        27,388
                                                   ----------  -----------  ------------
NET CASH PROVIDED BY OPERATING
  ACTIVITIES                                              (7)         (90)      (56,485)
INVESTING ACTIVITIES
  Increase in other assets                                                       13,366
  Purchase of equipment                                                          50,149
                                                   ----------  -----------  ------------
NET CASH USED IN INVESTING ACTIVITIES                                            63,515
FINANCING ACTIVITIES
  Sale of common stock                                                          120,000
                                                   ----------  -----------  ------------
INCREASE (DECREASE) IN CASH AND CASH
  EQUIVALENTS                                             (7)         (90)            0
Cash and cash equivalents at the beginning of the
  period                                                   7           97             0
                                                   ----------  -----------  ------------
CASH AND CASH EQUIVALENTS AT THE END OF
  THE PERIOD                                        $      0   $        7   $         0
                                                   ==========  ===========  ============
</TABLE>

    The accompanying notes are an integral part of the financial statements.


                                     F - 4
<PAGE>
<TABLE>
<CAPTION>
                             HOME WEB, INCORPORATED
                          (A Development Stage Company)
                        STATEMENT OF SHAREHOLDERS' EQUITY
                    September 30, 2000 and December 31, 1999
                                   (Audited)

            1999
            ----
                                                                      Deficit
                                                                     Accumulated
                                  Common stock                         During
                               --------------------       Paid in    Development
                               Shares        Amount       Capital       Stage        Total
                             -----------  -------------  ----------  ------------  --------
<S>                          <C>          <C>            <C>         <C>           <C>
Balance,
   December 31, 1998         27,497,000   $     27,497   $1,347,003  $(1,315,513)  $58,987

Common stock issued              10,000             10          490                    500

Net loss for the period
   ended December 31, 1999                                               (29,765)  (29,765)
                             -----------  -------------  ----------  ------------  --------
                             27,507,000   $     27,507   $1,347,493  $(1,345,278)  $29,722



            2000
            ----

Balance,
   December 31, 1999         27,507,000   $     27,507   $1,347,493  $(1,345,278)  $29,722

February 23, 2000,
 forward stock split          5,369,400
Net loss for the period
   ended September 30, 2000                                               (3,799)   (3,799)
                             -----------  -------------  ----------  ------------  --------
                             32,876,400   $  27,507.00   $1,347,493  $(1,349,077)  $25,923
                             ===========  =============  ==========  ============  ========
</TABLE>

    The accompanying notes are an integral part of the financial statements.


                                     F - 5
<PAGE>
                             HOME WEB, INCORPORATED
                          (A Development Stage Company)

                   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
                    September 30, 2000 and December 31, 1999
                                   (Audited)

Development  Stage  Company
---------------------------
     Home Web, Inc. (the "Company") is a development stage company as defined in
     the  Financial  Accounting  Standards  Board No. 7. The Company is devoting
     substantially all of its present efforts in securing and establishing a new
     business,   and  although  planned  principal  operations  have  commenced,
     substantial revenues have yet to be realized.

Use  of  estimates
------------------
     The  preparation of the financial  statements in conformity  with generally
     accepted  accounting  principles  requires management to make estimates and
     assumptions   that  affect  certain   reported   amounts  and  disclosures.
     Accordingly, actual results could differ from these estimates.

Cash  equivalents
-----------------
     For the purpose of the statement of cash flows,  the company  considers all
     highly  liquid debt  instruments  purchased  with the original  maturity of
     three months or less to be cash equivalents.

Organization  and  Business  Start  Up  and  Amortization
---------------------------------------------------------
     Organization costs were expensed during the period ending March 31, 1999 in
     accordance with SOP 98-5. Management made the election to expense the costs
     for years beginning January 1, 1999.

Income  Taxes
-------------
     Income taxes are provided for the tax effects of  transactions  reported in
     the financial  statements and consist of taxes  currently due plus deferred
     taxes related primarily to differences  between the recorded book basis and
     tax basis of assets and liabilities for financial and income tax reporting.
     The deferred  tax assets and  liabilities  represent  the future tax return
     consequences  of  those  differences,  which  will  either  be  taxable  or
     deductible  when the  assets  and  liabilities  are  recovered  or  settle.
     Deferred taxes are also recognized for operating  losses that are available
     to offset  future  taxable  income and tax credits  that are  available  to
     offset future federal income taxes.

Common  Stock
-------------
     Common  stock is at .001  par  value  with  50,000,000  shares  authorized,
     32,876,400 were outstanding as of September 30, 2000 and 27,507,000 for the
     period ending December 31, 1999.


                                     F - 6
<PAGE>
                             HOME WEB, INCORPORATED
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                    September 30, 2000 and December 31, 1999
                                   (Audited)

NOTE  A:  Background
          ----------

     The  Company  was  incorporated  under  the laws of the  State of Nevada on
     September  15, 1995.  The  principal  activities  of the Company,  from the
     beginning of the development  stage, have been  organizational  matters and
     the sale of stock.  The  Company was formed to sell  wholesale  gourmet and
     specialty  cheese on the Internet.  During the period ending  September 30,
     2000 and 1999 the Company had sales and  incurred  expenses  against  those
     sales, but the activity was immaterial for the purposes of SFAS No. 7.

NOTE  B:  Related  Party  Transactions
          ----------------------------

     During the period ending September 30, 2000 an affiliated  company advanced
     the Company $20,908. This money was used to pay off the accounts payable as
     of June 30, 2000. For the period ended December 31, 1999 the Company paid a
     total of  $5,400  in rent and  consulting  fees per an  agreement  with the
     affiliate.

NOTE  C:  Income  taxes
          -------------

     The benefit for income taxes from  operations  consisted  of the  following
     components:  current  tax  benefit of $5,458  for  September  30,  2000 and
     $4,458,  as of September 30, 1999  resulting  from a net loss before income
     taxes,  and  deferred  tax  expenses  of $ 5,458  and  $4,458  respectively
     resulting  from a valuation  allowance  recorded  against the  deferred tax
     asset resulting from net operating losses.  Net operating loss carryforward
     will expire in 2013.

     The  valuation  allowance  will  be  evaluated  at the  end of  each  year,
     considering  positive and negative evidence about whether the asset will be
     realized.  At the time,  the allowance will either be increased or reduced;
     reduction  would result in the  complete  elimination  of the  allowance if
     positive evidence  indicates that the value of the deferred tax asset is no
     longer required.

NOTE  D:  Change  in  Accounting  Year
          ----------------------------

     The Board of  Directors  elected to change the year end date of the Company
     to September  30. This change became  effective at September 30, 2000.  The
     financial  statements  are for the nine months ended while the December 31,
     2000 amounts are for a twelve month period.

NOTE  E:  Common  Stock
          -------------

     During the period ending September 30, 1999, pursuant to an exemption under
     Rule 504 of  Regulation D of the  Securities  Act of 1933,  as amended (the
     Act), the


                                     F - 7
<PAGE>
                             HOME WEB, INCORPORATED
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                    September 30, 2000 and December 31, 1999
                                   (Audited)

NOTE  E:  Continued
          ---------

     Company  sold solely to  accredited  and/or  sophisticated  investors,  its
     common stock. The only  transaction  during the period of December 31, 1999
     was 10,000 shares of stock issued to the corporate  counsel in exchange for
     legal services to the corporation.

     On February 10, 2000 the board of  directors  voted a 1.2:1  forward  stock
     split as of the record date of February 23, 2000.

NOTE  F:  Stock  options
          --------------

     It was also voted upon at the  organizational  meeting during 1997 to grant
     options to officers of the corporation and MVI, an affiliated company along
     with one of the  employees  of MVI.  The options can be exercised at $.001.
     The options to be exercised  are  1,250,000  and have no  expiration  date.
     These options are considered compensatory and the expense was recognized in
     the prior year.

     There  were no  options  exercised  during  the  nine-month  period  ending
     September 30, 2000.

NOTE  G:  Property,  equipment  and  depreciation
          ---------------------------------------

     Property and  equipment are recorded at cost.  Maintenance  and repairs are
     expensed as incurred; major renewals and betterments are capitalized.  When
     items of property and equipment are sold or retired,  the related costs and
     accumulated depreciation are removed from the accounts and any gain or loss
     is included in income.

     Depreciation  expense for the period ending  September 30, 2000 was $0. And
     $4,003 for the year ended December 31, 1999.

NOTE  H:  Major  customer
          ---------------

     The Company had a purchase commitment to purchase the Company's merchandise
     from a  non-affiliated  company.  This  customer  is also to take  physical
     possession  of the  Company's  major  assets  and use  those  assets in the
     ordinary course of its business. Terms are discussed more fully in Note I

NOTE  I:  Going  concern
          --------------

     As of  September  30,  2000,  the  Company  had net losses  from  operating
     activities which raise substantial doubt about its ability to continue as a
     going concern.


                                     F - 8
<PAGE>
                             HOME WEB, INCORPORATED
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                    September 30, 2000 and December 31, 1999
                                   (Audited)

NOTE  I:  Continued
          ---------

     The Company is in the process of raising  initial working capital through a
     public offering of its common stock, which is expected to provide liquidity
     until operations become  profitable.  The Company has obtained a commitment
     for up to $150,000 from a significant  shareholder,  Monterey Ventures, Inc
     for funding

     over the next  twelve  months.  The  funds  would  be paid  distributed  in
     increments per requests from the Company on an "as needed" basis. Under the
     agreement,  the Company can repay the borrowed  funds in  increments as the
     Company receives payment from its' customers.  Also in the credit agreement
     is any funds needed for longer than twelve months would be considered  long
     term debt.  This type of  funding,  if needed,  would be  structured  for a
     twenty four or  thirty-six  month payoff not to exceed $ 25,000 in requests
     in the first year of operations.

     The Company has signed an agreement  with Internet Food Company to purchase
     its' products.  Internet Food Company has already  penetrated the hotel and
     gift  basket  market  and has  further  developed  a web site to market its
     goods.  The  two  companies  are in the  process  of  identifying  specific
     products that Home Web. Inc. would supply wholesale.

     The Company's  ability to continue as a going  concern is dependent  upon a
     successful public offering and ultimately achieving profitable  operations.
     There is no assurance that the Company will be successful in its efforts to
     raise additional proceeds or achieve profitable  operations.  The financial
     statements  do not  include  any  adjustments  that might  result  from the
     outcome of this uncertainty.

NOTE  J:  Subsequent  event
          -----------------

     On October 16,  2000,  principal  shareholders  of the Company  returned to
     treasury  28,800,000 shares of Common Stock as contemplated by an Agreement
     and Plan of  Reorganization  with Duro  Enzyme  Products  Inc.  executed on
     August 1, 2000. On September 29, 2000, the Company  authorized the issuance
     of 28,800,000 shares of Common Stock of the Company to shareholders of Duro
     Enzyme Products Inc. On October 16, 2000, the Company issued the 28,800,000
     shares of Common  Stock  pursuant to a voluntary  share  exchange  with the
     shareholders of Duro Enzyme  Products Inc. The 28,800,000  shares issued to
     shareholders  of Duro  Enzyme  Products  Inc.  represented  over 80% of the
     issued and outstanding  shares of Common Stock of the Company and therefore
     resulted in a change in control of the Company. By virtue of this issuance,
     the Company  acquired  100% of the issued and  outstanding  capital of Duro
     Enzyme Products Inc., which had net assets of $1,023,515 as of


                                     F - 9
<PAGE>
                             HOME WEB, INCORPORATED
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                    September 30, 2000 and December 31, 1999
                                   (Audited)

NOTE  J:  Continued
          ---------

     September  30, 2000.  Pro forma net assets of the  combined  entities as of
     September 30, 2000 were  $1,076,826.  For more  information on the business
     combination, please see the  Home.Web, Inc.  report on  the Amendment No. 1
     to Form 8-K dated October 16, 2000 and filed on December 29, 2000, with the
     SEC.

NOTE  K:  Stock  Options
          --------------

     Stock that is issued for services rendered is recorded at the fair value of
     the stock in the year that the stock is given and recorded as an expense in
     the same year.


                                     F - 10
<PAGE>
The  Raber  Mattuck  Group
Chartered  Accountants

  Suite 318, North Tower, Oakridge Centre, 650 West 41st Avenue, Vancouver B.C.,
                                     V5Z 2M9
         Telephone: (604) 435-5655    Facsimile: (604) 435-1913    E-mail:
                                rmca@uniserve.com
--------------------------------------------------------------------------------


                                AUDITORS' REPORT


--------------------------------------------------------------------------------


To  the  Shareholder  of  Duro  Enzyme  Products  Inc.:

We  have  audited the consolidated balance sheet of Duro Enzyme Products Inc. as
at  September  30,  2000 and the consolidated statements of loss and deficit and
changes  in  financial  position for the ten months then ended.  These financial
statements  are  the  responsibility  of  the  company's  management.  Our
responsibility  is  to express an opinion on these financial statements based on
our  audit.

We conducted our audit in accordance with generally accepted auditing standards.
Those  standards  require that we plan and perform an audit to obtain reasonable
assurance  whether  the  financial statements are free of material misstatement.
An  audit  includes  examining, on a test basis, evidence supporting the amounts
and  disclosures  in the financial statements.  An audit also includes assessing
the  accounting principals used and significant estimates made by management, as
well  as  evaluating  the  overall  financial  statement  presentation.

In  our  opinion,  these  financial  statements  present fairly, in all material
respects, the financial position of the company as at September 30, 2000 and the
results  of  its  operations  and  the changes in its financial position for the
period  ended  in  accordance  with  generally  accepted  accounting principles.


                                              /s/    "Raber Mattuck"
                                              ----------------------------------
                                              CHARTERED ACCOUNTANTS



Vancouver,  British  Columbia
October  17,  2000


                                     F - 11
<PAGE>
                          DURO  ENZYME  PRODUCTS  INC.
                           CONSOLIDATED BALANCE SHEET
                            AS AT SEPTEMBER 30, 2000
                                   (Audited)


                                       U.S. $
                                     -----------
ASSETS
------

CURRENT ASSET
     Accounts receivable             $        1
     Prepaid expenses                    23,514
                                     -----------
                                         23,515

LICENSE (Note 2 (c) and 6 (a))        1,000,000
                                     -----------


TOTAL ASSETS                         $1,023,515
                                     ===========

LIABILITIES & SHAREHOLDER'S EQUITY
----------------------------------

CURRENT LIABILITIES

     Accounts Payable (Note 3)       $   27,446
     Note Payable (Note 4)            1,000,000
                                     -----------
                                      1,027,446
                                     -----------

SHAREHOLDER'S EQUITY
--------------------

CAPITAL STOCK (Note 5)                        1

DEFICIT                                  (3,932)
                                     -----------

                                         (3,931)
                                     -----------

                                     $1,023,515
                                     ===========

                 See accompanying notes.


                                     F - 12
<PAGE>
<TABLE>
<CAPTION>
                          DURO  ENZYME  PRODUCTS  INC.
                         CONSOLIDATED STATEMENT OF LOSS
                FOR THE 10 MONTH PERIOD ENDED SEPTEMBER 30, 2000
                                   (Audited)


                                                          U.S. $
                                                         --------


<S>                                                      <C>
EXPENSES
     Filing Fees                                            2,699
     Interest Expense                                       1,233
                                                         --------

NET LOSS AND DEFICIT                                      $ 3,932
                                                         ========
</TABLE>

                         See  accompanying  notes.


                                     F - 13
<PAGE>
<TABLE>
<CAPTION>
                            DURO ENZYME PRODUCTS INC.
             CONSOLIDATED STATEMENT OF CHANGES IN FINANCIAL POSITION
                FOR THE 10 MONTH PERIOD ENDED SEPTEMBER 30, 2000
                                   (Audited)

                                                              U.S. $
                                                           ------------
<S>                                                        <C>
CASH RESOURCES PROVIDED BY (USED IN)
OPERATING ACTIVITES
     Net Loss                                              $    (3,932)

Cash generated from (used for) operating working capital
     Accounts receivable                                             1
     Prepaid expenses                                          (23,514)
     Accounts payable and accrued liabilities                   27,446
                                                           ------------

                                                                    (1)
                                                           ------------
CASH RESOURCES PROVIDED BY (USED IN)
FINANCING ACTIVITIES
     Share capital                                                   1
     Note Payable                                            1,000,000
                                                           ------------

                                                             1,000,001
                                                           ------------
CASH RESOURCES PROVIDED BY (USED IN)
INVESTING ACTIVITIES
     Acquisition of license                                 (1,000,000)
                                                           ------------

                                                            (1,000,000)
                                                           ------------

INCREASE (DECREASE) IN CASH                                          -

CASH AND TERM DEPOSITS, beginning of year                            -
                                                           ------------

CASH AND TERM DEPOSITS, end of year                        $         -
                                                           ============
</TABLE>

                             See accompanying notes.


                                     F - 14
<PAGE>
                            DURO ENZYME PRODUCTS INC.
                          NOTES TO FINANCIAL STATEMENTS
                   FOR THE 10 MONTHS ENDED SEPTEMBER 30, 2000
                                   (Audited)


1.   NATURE  OF  BUSINESS  AND  STATUS  OF  ACTIVITIES

     Duro Enzyme Products Inc. (the "Company") was  incorporated in Nevada,  USA
     on November 29, 1999, and is a private company.

     Duro  Enzyme  Products  Inc.  has the  license to utilize  and  exploit the
     DuroZyme  Plant  and  3SF  Technology   anywhere  in  the  world.   Through
     application of the technology,  the Company can manufacture unique,  stable
     and natural enzymes and specialty end products.

     The Company has investments in two subsidiary, as follows:

     Company                                      Nature  of  Business

     Duro  Enzyme  Solutions  Inc.
     (100%  owned)  -  Nevada  Corporation        Licensor  of  Technology

     Duro  Enzyme  Solutions  Inc.
     (100%  owned)  -  B.C.  Corporation          Canadian  Subsidiary

2.  SIGNIFICANT  ACCOUNTING  POLICIES

<TABLE>
<CAPTION>
<C>                             <S>
(a)   PRINCIPLES OF ACCOUNTING  These consolidated financial statements have been
                                prepared in accordance with accounting principles
                                generally accepted in Canada applicable to a going
                                concern, which assumes that the Company will
                                continue operation for a reasonable period of time and
                                will be able to realize its assets and discharge its
                                liabilities and commitments in the normal course of
                                operations.

                                These principles can differ in certain material respects from
                                those accounting principles generally accepted in the
                                United States but no material differences exist in these
                                statements.


                                     F - 15
<PAGE>
(b)   BASIS OF CONSOLIDATION    These financial statements have been prepared using the
----------------------------
                                purchase method of consolidation.  The assets and
                                liabilities of acquired companies are initially recorded at
                                their cost.  The results of operations of the acquired
                                companies are included from the dates of acquisition.  All
                                significant intercompany transactions and balances have
                                been eliminated on consolidation.

(c)   LICENSES                  License rights are recorded at cost and are amortized on a
--------------
                                straight-line basis over the license period (10 years) which
                                is the Company's estimated period of benefit for these
                                costs.
</TABLE>


3.   ACCOUNTS  PAYABLE

     Included in accounts payable is $25,213 US owing to the President, Director
     and Sole Shareholder of the Company.

4.   NOTE  PAYABLE

     The Company,  in connection with its  acquisition of the license  agreement
     (Note 6 (a)) is indebted by way of a  $1,000,000  US note  payable,  due on
     demand at five percent (5%) rate of interest  payable both before and after
     maturity.  Interest of $1,233 US has been  accrued but unpaid to  September
     30, 2000.

5.   CAPITAL  STOCK

     The Company has  authorized  share capital of 25,000,000  common shares par
     value of $0.01US. Only 1 share has been issued.

6.   SIGNIFICANT  AGREEMENTS

     The Company has entered  into  several  significant  agreements  during the
     operating period as follows:

     a)   License  and  Distribution   Agreement.   The  Company,   through  its
          subsidiary  entered  into a  License  and  Distribution  Agreement  on
          September 21, 2000 to utilize and exploit the DuroZyme  plants and the
          advanced  3SF  Technology  anywhere  in  the  world.  The  License  is
          $1,000,000   US  and  was  satisfied  by  a  Note  payable  (Note  4).
          Amortization has not been recorded during the period (Note 2 (e)). The
          License  Agreement  also  calls for an  additional  payment of two and
          one-half percent (2.5%) of gross revenue.


                                     F - 16
<PAGE>
     b)   Research and Development  Service  Agreement.  The Company has entered
          two separate agreements (one for the United States and one for Canada)
          on September 21, 2000 to retain the services of a Consultant to be the
          Company's prime supplier, to provide research, development and related
          consulting  services.  These  services are provided at a cost plus 15%
          rate. This contract is for five (5) years and renewable  automatically
          if not terminated.


                                     F - 17
<PAGE>
<TABLE>
<CAPTION>
                                 HOME.WEB, INC.
                      PROFORMA - CONSOLIDATED BALANCE SHEET
                      As At September 30, 2000 (Unaudited)



                                                                U.S. $
                                                            ------------
ASSETS
------
<S>                                                         <C>
CURRENT ASSET
     Accounts receivable                                    $     1,451
     Prepaid expenses                                            23,514
                                                            ------------
                                                                 23,515

CAPITAL ASSETS                                                   40,861
LICENSE                                                       1,000,000
TRADE NAME                                                       11,000
                                                            ------------

TOTAL ASSETS                                                $ 1,076,826
                                                            ============

LIABILITIES & SHAREHOLDER'S EQUITY
----------------------------------

CURRENT LIABILITIES
     Accounts Payable                                       $    28,872
     Note Payable                                             1,000,000
     Loan from affiliate                                         25,962
                                                            ------------
                                                              1,054,834
                                                            ------------

SHAREHOLDER'S EQUITY
--------------------

CAPITAL STOCK                                                    27,508
PAID IN CAPITAL                                               1,347,493
DEFICIT                                                      (1,353,009)
                                                            ------------
                                                                 21,992

                                                            $ 1,076,826
                                                            ============
</TABLE>


                                     F - 18
<PAGE>
                                 HOME.WEB, INC.
                    PROFORMA - CONSOLIDATED STATEMENT OF LOSS
          For the 9 Month Period Ended September 30, 2000 (Unaudited)


                                                               U.S. $
                                                            ------------

EXPENSES
   Consulting Fees                                                 2,929
   Filling Fees                                                    2,699
   Interest Expense                                                1,233
   Office supplies                                                    70
                                                            ------------

NET  LOSS                                                         $6,931
                                                            ============


                                     F - 19
<PAGE>
                                 HOME.WEB, INC.
                    PROFORMA - CONSOLIDATED STATEMENT OF LOSS
           For the 12 Month Period Ended December 31, 1999 (Unaudited)


                                                               U.S. $
                                                            ------------

REVENUE                                                             528
COST OF SALES                                                       523
                                                            ------------
  GROSS MARGIN                                                        5

EXPENSES
   Advertising                                                        7
   Consulting Fees                                                5,500
   Depreciation                                                   4,003
   Filling Fees                                                   1,000
   License and Taxes                                                145
   Office help                                                    1,591
   Office supplies                                                  588
   Travel                                                            54
   Rent                                                             248
   Business start up costs                                       15,318
                                                            ------------
TOTAL EXPENSES                                                   28,454
                                                            ------------
LOSS FROM OPERATION                                             (28,449)
OTHER  INCOME  (EXPENSES)
   Nondeductible penalties                                         (716)
   State tax expense                                             (1,600)
                                                            ------------
   Total other expense                                           (2,316)

NET LOSS                                                        (30,765)
                                                            ============

NET  LOSS  PER  COMMON  STOCK                                  $(0.0011)
                                                            ------------

WEIGHTED AVERAGE OF SHARES OUTSTANDING                        27,157,000
                                                            ------------


                                     F - 20
<PAGE>
                                  EXHIBIT INDEX


EXHIBIT
NUMBER   DESCRIPTION
-------  --------------------------------------------------------------------

    4.1  Specimen Stock Certificate for Shares of Common Stock of the Company

   23.1  Consent of Hawkins Accounting, Independent Auditor

   27.1  Financial Data Schedule


<PAGE>